CliffBio
small molecule

JYLAMVO

METHOTREXATE

Loss of exclusivityOctober 2035latest FDA-listed patent expiry
CompanyShorla Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameJYLAMVO
Active ingredientMETHOTREXATE
Strength2MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2022
Marketing statusRX

Listed patents

PatentExpiresType
11129833October 2035product
12605385October 2035product
11771701October 2034product

More from Shorla Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JYLAMVO patent cliff — loss of exclusivity October 2035 | CliffBio